Navigation Links
China PharmaHub Reviews 2010 and Recent Accomplishments
Date:3/24/2011

o obtain the rights to sell such products and devices in China.

Corporate Developments

  • Created subsidiary CPC NuLife, Inc. to commercialize CPC001, an irradiated microsphere device, in worldwide markets.
  • Founded joint venture Akanas Therapeutics, a China PharmaHub joint venture dedicated to the commercialization of therapeutics derived from its humanized antibody platform technology.
  • Created MediTherX, a China PharmaHub joint venture engaged in the commercialization of EGFR humanized antibody candidates.
  • Formed True Value Capital, Inc., a wholly owned China PharmaHub subsidiary engaged in the commercialization of non-pharmaceutical based technology acquired from the U.S.

About China PharmaHub Corp.

China PharmaHub Corp. is a development stage company engaged in the business of licensing, developing and commercializing innovative products for a wide variety of human diseases from biopharmaceutical companies based in the United States or China. PharmaHub brings a unique blend of relationships and resources to assist scientists and companies to develop, commercialize, market and sell pharmaceutical, biotechnology and healthcare products, as well as offer improved, cost-effective alternatives to current methods of treatment or enable the discovery, research and development of new medicines. PharmaHub's corporate headquarters are located in Los Angeles and Boston. More information on China PharmaHub is available at www.chnpharmahub.com.

Forward-Looking Statements

This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends su
'/>"/>

SOURCE China PharmaHub Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China
2. China PharmaHub In-Licenses Universal Donor Red Blood Cells Technology Exclusively From University of California, San Diego
3. China-Biotics Expands Product Supplied to Bright Dairy
4. Huifeng Bio-Pharmaceutical Technology, Inc. to Present at the 2011 Rodman & Renshaw Annual China Investment Conference in Shanghai
5. China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results
6. ShengdaTech to Present at Rodman & Renshaw Annual China Investment Conference in Shanghai
7. China Cord Blood Corporation Forms Zhejiang Subsidiary
8. China Cord Blood Corporation Announces Results of 2010 Annual General Meeting
9. China Cord Blood Corporation to Announce Third Quarter Fiscal 2011 Financial Results
10. China-Biotics to Report Fiscal Year 2011 Third Quarter Financial Results on February 9
11. China-Biotics, Inc. Provides Preliminary FY2011Third Quarter Revenue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or ... any jurisdiction where to do so would constitute a violation ... plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ... it has held a meeting with representatives of AbbVie. ... prior agreement or approval of AbbVie. A further ...
(Date:7/11/2014)... MISSISSAUGA, ON , July 11, 2014 /CNW/ - ... Canada approved APTIOM TM (eslicarbazepine acetate) for use ... partial-onset seizures in patients with epilepsy who are not ... not indicated for use in patients under 18 years ... the most common neurological disorders and according to Epilepsy ...
(Date:7/10/2014)... Canada (PRWEB) July 10, 2014 ... present in very low abundance and are often ... challenging and time-consuming. , Join presenters Dr. Rowel ... and Dr. John Anders, Head of Quality at ... spectrometer-based approach that can speed detection and quantitation ...
(Date:7/10/2014)... 2014 Unraveling life’s mysteries can intrigue, ... Archer Family purchased a DNA test to ... up with a lifetime of memories, sharing, and closeness. ... members’ DNA genuinely brought the family closer together. ... into genetic history and prior to taking the ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... Corporation is,pleased to announce it has obtained US FDA ... C-QUR Edge(TM) V-Patch and C-QUR Lite(TM),V-Patch., These new ... and,reinforcement of soft tissue, including hernia repair -- a ... each year. This novel,technology combines Atrium,s ProLite Ultra(TM) polypropylene ...
... ENMD-2076, ROCKVILLE, Md., May 8 ... developing therapeutics for,the treatment of cancer and ... has joined the University of Colorado Cancer,Center ... ENMD-2076 in advanced cancer,patients. Dr. Geoffrey Shapiro, ...
... May 7, 2008 / b3c newswire / – ... entered into a joint agreement to supply customers ... complex structures. , Under the agreement, CRELUX and ... crystal-grade protein kinase portfolio, optimized and quality-controlled for ...
Cached Biology Technology:Atrium Medical Receives FDA Approval for its Novel C-QUR Lite(TM) V-Patch and C-QUR Edge(TM) V-Patch 2Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor 2Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor 3CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform 2CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform 3
(Date:7/11/2014)... has demonstrated that transplantation of mesenchymal stem cells can ... mouse models of Alzheimer,s disease (AD) and improve tissue ... Few studies are reported on the therapeutic effect of ... and on the effect on oxidative injury and neurogenesis ... and her team, School of Life Sciences, Tsinghua University, ...
(Date:7/11/2014)... study the proteins that let nerve cells send out ... upon a biological tactic that may offer a new ... safe and environmentally responsible way. , Their findingthat ... species and harmless for a closely related onesuggests that ... harming beneficial species like bees. A summary of the ...
(Date:7/10/2014)... 30, 2014  Aware, Inc. (NASDAQ: AWRE ... previously announced on June 26, 2014 that its Board ... $1.75 per share, or approximately $40 million in total.  ... 2014 and a payment date of July 24, 2014.  ... had set an ex-dividend date for this special cash ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... Everyone wants to live in the nicest possible house, ... at Tufts University,s School of Arts and Sciences and ... locate new and improved housing using previously unknown social ... experiments and computer models to uncover some surprising new ...
... Here,s another reason to kick the soda habit. New ... ( http://www.fasebj.org ) shows that high levels of phosphates ... than once thought. That,s because researchers found that the ... phosphate levels may also increase the prevalence and severity ...
... 23, 2010) Moffitt Cancer Center announces steadily growing ... for selecting chemotherapy for Non Small Lung Cancer patients. ... with lung cancer. The ERCC1 Analysis measures ERCC1 ... The correlation between ERCC1 levels and therapy ...
Cached Biology News:Social networking helps hermit crabs find homes 2Social networking helps hermit crabs find homes 3Phosphorous in sodas and processed foods accelerates signs of aging say Harvard scientists 2Moffitt Cancer Center: Growing interest in prognostic test for non-small cell lung cancer 2